Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...
Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector
Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...
Fierce Pharma1h
With Eli Lilly flying high, CEO David Ricks collects 10% raise to $29.2M
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
Eli Lilly (LLY) Slid on Rare Revenue Miss in its 3Q Update
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...
SWI swissinfo.ch2h
Novo’s New Obesity Drug Disappoints Again, This Time in Diabetes
Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot ...
Novo Nordisk shares slide 6% after weight loss drug trial disappoints
Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, ...
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
BioSpace10h
GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...